Navigation Links
China Bionanometer Industries Corporation Announces Record Second Quarter 2007 Results
Date:1/29/2008

the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to, the Company's ability to raise additional capital to finance the Company's activities; the effectiveness, profitability, and the marketability of its products; legal and regulatory risks associated with the share exchange; the future trading of the common stock of the Company; the ability of the Company to operate as a public company; the period of time for which its current liquidity will enable the Company to fund its operations; the Company's ability to protect its proprietary information; general economic and business conditions; the volatility of the Company's operating results and financial condition; the Company's ability to attract or retain qualified senior management personnel and research and development staff; and other risks detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company and the industry. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward looking statements are reasonable, they cannot assure you that their expectations will turn out to be correct, and investors are cautioned that actual results may differ materially from the anticipated results.

-- FINANCIAL TABLES FOLLOW --

Landway Bionanometer Technology Joint-stock Co., Ltd

Condensed Statements of Operations and Comprehensive Income

(US$-Unaudited)


'/>"/>

SOURCE Xi'an Landway Bionanometer Technology Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. AMDL Signs 100 Strategic Cooperation Agreements in China for Its JPGreen Clinics; Gross Sales Per Each Location Could Exceed $400,000
2. PPD Expands Global Central Lab Services into China
3. WuXi PharmaTech (NYSE: WX) CEO Honored among the 2007 China Top 10 Influential Entrepreneurs
4. China Biologic Products Gains Financial Support from Shandong Provincial Government on the Improvement of Production Facilities
5. China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program
6. Quintiles Central Lab, Clinical Development in China to Expand, Relocate to New Facility
7. China Medical Technologies Completes Acquisition of BBE
8. Three Steps to Boost Asymchems Investment in China
9. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter FY 2008 Results
10. AMDLs First Full Service JPGreen Health and Personal Care Center Set to Open in Hangzhou, China
11. CYIG Awarded Chinas "Top 100 Enterprises" in New Pharmaceuticals, Selected as National "Torch Plan Key High-Tech Enterprise"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... and PARIS , ... AgBiome, and Genective, key developer of biotech crops, ... discovery of new generations of insect control traits. ... control to counter the realities of advancing insect ... aligning AgBiome,s unique insect control technology with Genective,s ...
(Date:7/1/2015)... HAMILTON, Bermuda , July 1, 2015 /PRNewswire/ ... biopharmaceutical company focused on the treatment of dementia, ... investor briefing on July 22 at 5:45 p.m. ... at the Alzheimer,s Association International Conference 2015 (AAIC). ... following remarks: , Dr. Lawrence ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... pathogen transmission. CTI’ new Medical Joysticks have an impermeable molecular barrier protection ... an operator control device that will increase healthcare worker safety and reduce financial ...
(Date:6/30/2015)... , ... June 30, 2015 , ... ... hosting a webinar to provide advanced scientific research into new classes of Nanoscale ... and energy. Touted as 'the wonder material of the 21st Century' by ...
Breaking Biology Technology:AgBiome and Genective collaborate to create novel insect-resistant crops 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 3How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 4
... 25, 2012 Covance Inc. (NYSE: CVD ... ended December 31, 2011 of $0.35 per diluted share. ... diluted share in charges, approximately $0.10 of which relates ... $0.11 of which relates to the termination of a ...
... HANOVER, N.J., Jan. 25, 2012 Novartis Pharmaceuticals Corporation (NPC) ... and the Class, today announced an agreement to resolve the ... in the US District Court for the Southern District of ... the ongoing proceedings and provide a payment of up to ...
... PARK, Calif., Jan. 24, 2012 SRI International has ... the time required for researchers to construct genome-scale models ... of metabolic and physical processes that determine the physiological ... used to predict cell growth rate, combinations of chemicals ...
Cached Biology Technology:Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 2Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 3Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 4Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 5Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 6Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 7Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 8Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 9Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 10Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 11Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 12Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 13Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 14Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 15Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims 2Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims 3Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims 4New Software from SRI Speeds Development of Genome-Scale Models for Drug and Fuel Research 2
(Date:6/24/2015)... 24, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that Sharp has selected its industry-leading ... for its latest flagship smartphone device, the AQUOS ... million shipments of its fingerprint ID sensor technology, ... scalability and leadership in the biometrics market through ...
(Date:6/23/2015)... 22, 2015 Research ... of the "Body-Worn Temperature Sensors Market - ... Forecast 2014 - 2020" report to their ... of the global body-worn temperature sensors market. The ... on the basis of types, care setting, patient ...
(Date:6/18/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market announces that its Wocket® smart wallet will be ... Mark", scheduled to air on WABC Radio (am770) in ... The broadcast air- time for the extensive ... NXT-ID, Inc.,s CEO Gino Pereira will be discussing ...
Breaking Biology News(10 mins):Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3
... electronics for next-generation biomedical devices has prompted the ... at Cornell, funded by the National Science Foundation ... million over five years from NSF,s Integrative Graduate ... fellows will work in teams to design and ...
... It all started with flowers: in the nineties of ... of a particular gene in petunias inhibited its activity ... few years later it was found that the mechanism ... the cells. Finally, in the late nineties the Nobel ...
... news for public health: Bioengineering researchers from the EPFL ... that can deliver vaccines more effectively, with fewer side ... current vaccine technologies. Described in an article ... the vaccine delivery platform is a deceptively simple combination ...
Cached Biology News:IGERT fellows to design biodevices using flexible electronics 2Mechanism for the in-vivo transport of siRNA 2Mechanism for the in-vivo transport of siRNA 3New nanoparticle vaccine is more effective but less expensive 2New nanoparticle vaccine is more effective but less expensive 3
BDFastImmune? IFN-gamma /CD69/CD4/CD3 Storage Temperature: Refrigerate(2 to 8C)...
MAb to Transferrin Dry Ice: No Preservative: NaN3 Availability When Not in Inventory: 14-21 Business Days...
Rabbit polyclonal to Phosphothreonine-X-Phosphotyrosine (HRP) ( Abpromise for all tested applications)....
Rabbit polyclonal to IRS1 (phospho S636) ( Abpromise for all tested applications). entrezGeneID: 3667 SwissProtID: P35568...
Biology Products: